Catalyst Pharmaceuticals up 18% after resumption following Teva settlement

Shares of Catalyst Pharmaceuticals (CPRX) have resumed trading and are higher after the company announced that the company and its licensor SERB S.A. have entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals (TEVA) that resolves the patent litigation brought by Catalyst and SERB in response to Teva’s Abbreviated New Drug Application for a generic version of Firdapse 10 mg tablets prior to expiration of the applicable patents. Catalyst shares are up $3.60, or 18%, to $23.13 after resuming following a trading halt.